Is pCR a Reliable Survival Surrogate in Breast Cancer Trials?

Pathologic complete response (pCR) is not a reliable surrogate endpoint in neoadjuvant therapy trials for early breast cancer; alternatives are needed, researchers said.
Medscape Medical News

source https://www.medscape.com/viewarticle/983165?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?